A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab versus Placebo in Prodromal AD

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223374

Enrollment

Unknown

Registered

2016-11-13

Start date

2016-11-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prodromal AD

Interventions

investigational material(s) Generic name etc : Solanezumab INN of investigational material : Therapeutic category code : 119 Other agents affecting central nervous system Dosage and Administration fo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Is aged 55-85 years - Has a diagnosis of a clinical syndrome of cognitive impairment consistent with prodromal AD per IWG diagnostic criteria or MCI due to AD per NIA-AA diagnostic criteria - Has a PET scan or CSF result with the presence of amyloid pathology

Exclusion criteria

Exclusion criteria:

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026